Volume 2, Issue 5

Individualizing Treatment with New & Emerging Therapies

In this issue:

Personalizing treatment for patients with MS is hugely challenging. To be successful, clinicians need to balance many factors - an unpredictable disease course with unpredictable relapse rates, idiosyncratic drug reactions, lesion topography and severity - for every patient. What can help clinicians better manage this juggling act?

In this issue, Drs. Daniel Ontaneda, Jenny Feng, and Gabrielle Macaron from the Cleveland Clinic analyze recent publications describing the effects new and emerging treatment options may have on individualizing MS therapy.

Learning objectives:

  • Describe personalized therapy based on predictors of disease worsening and the risk profile of particular therapy options.
  • Explain the need for more effective agents in treating progressive MS.
  • Summarize the recently published trials of therapies for progressive MS.

Authors:

Jenny Feng, MD
Jenny Feng, MD

Neuroimmunology Fellow
Cleveland Clinic Neurological Institute
Cleveland, OH 

Daniel Ontaneda, MD
Daniel Ontaneda, MD

Staff Neurologist
Cleveland Clinic Neurological Institute
Cleveland, OH

Gabrielle Macaron, MD
Gabrielle Macaron, MD

Neuroimmunology Fellow
Cleveland Clinic Neurological Institute
Cleveland, OH

Program Director:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Length of activity:

1.0 hour Physicians

Launch date: May 18, 2019
Expiration date: May 17, 2021